for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-U.S. FDA Approves Novartis’ Updated Beovu Label - Statement

June 11 (Reuters) - Novartis AG:

* US FDA APPROVES UPDATED NOVARTIS BEOVU® LABEL, TO INCLUDE ADDITIONAL SAFETY INFORMATION

* NOVARTIS IS CONFIDENT THAT BEOVU CONTINUES TO REPRESENT AN IMPORTANT TREATMENT OPTION FOR PATIENTS WITH WET AMD, WITH AN OVERALL FAVORABLE BENEFIT/RISK PROFILE

* UPDATE TO US LABEL INCLUDES ADDITION OF SUB-SECTION DEDICATED TO RETINAL VASCULITIS AND/OR RETINAL VASCULAR OCCLUSION Source text: Further company coverage: (Berlin Speed Desk)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up